AYTU BIOPHARMA INC(NASDAQ:AYTU) stock Fundamental Analysis

Fundamental Rating

Overall AYTU gets a fundamental rating of 3 out of 10. We evaluated AYTU against 194 industry peers in the Pharmaceuticals industry. AYTU may be in some trouble as it scores bad on both profitability and health. AYTU is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

AYTU had negative earnings in the past year.

In the past year AYTU had a positive cash flow from operations.

AYTU had negative earnings in each of the past 5 years.

In the past 5 years AYTU always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of AYTU (-4.51%) is better than 76.76% of its industry peers.

AYTU has a Return On Equity of -17.04%. This is in the better half of the industry: AYTU outperforms 72.97% of its industry peers.

		Industry Rank	Sector Rank
ROA	-4.51%
ROE	-17.04%
ROIC	N/A

ROA(3y)-35%

ROA(5y)-27.17%

ROE(3y)-112.19%

ROE(5y)-78.65%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 67.43%, AYTU is doing good in the industry, outperforming 70.81% of the companies in the same industry.

AYTU's Gross Margin has been stable in the last couple of years.

AYTU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	67.43%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.82%

GM growth 5Y-0.72%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AYTU does not have a ROIC to compare to the WACC, probably because it is not profitable.

AYTU has more shares outstanding than it did 1 year ago.

The number of shares outstanding for AYTU has been increased compared to 5 years ago.

The debt/assets ratio for AYTU is higher compared to a year ago.

2.2 Solvency

AYTU has an Altman-Z score of -3.31. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -3.31, AYTU is not doing good in the industry: 61.62% of the companies in the same industry are doing better.

The Debt to FCF ratio of AYTU is 29.85, which is on the high side as it means it would take AYTU, 29.85 years of fcf income to pay off all of its debts.

AYTU has a Debt to FCF ratio of 29.85. This is in the better half of the industry: AYTU outperforms 77.84% of its industry peers.

AYTU has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of AYTU (0.45) is worse than 63.24% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.45
Debt/FCF	29.85
Altman-Z	-3.31

ROIC/WACCN/A

WACC18.78%

2.3 Liquidity

AYTU has a Current Ratio of 0.98. This is a bad value and indicates that AYTU is not financially healthy enough and could expect problems in meeting its short term obligations.

AYTU has a worse Current ratio (0.98) than 87.03% of its industry peers.

AYTU has a Quick Ratio of 0.98. This is a bad value and indicates that AYTU is not financially healthy enough and could expect problems in meeting its short term obligations.

AYTU's Quick ratio of 0.81 is on the low side compared to the rest of the industry. AYTU is outperformed by 85.41% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.98
Quick Ratio	0.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.29% over the past year.

AYTU shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -30.18%.

The Revenue has been growing by 61.82% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)71.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-550%

Revenue 1Y (TTM)-30.18%

Revenue growth 3Y7.28%

Revenue growth 5Y61.82%

Sales Q2Q%-29.27%

3.2 Future

AYTU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.64% yearly.

AYTU is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.72% yearly.

EPS Next Y125.68%

EPS Next 2Y57.75%

EPS Next 3Y35.64%

EPS Next 5YN/A

Revenue Next Year-17.49%

Revenue Next 2Y-5.54%

Revenue Next 3Y-3.13%

Revenue Next 5Y9.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AYTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

A Price/Forward Earnings ratio of 0.97 indicates a rather cheap valuation of AYTU.

Based on the Price/Forward Earnings ratio, AYTU is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.

The average S&P500 Price/Forward Earnings ratio is at 22.68. AYTU is valued rather cheaply when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.97

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, AYTU is valued cheaply inside the industry as 88.65% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	15.64
EV/EBITDA	-0.11

4.3 Compensation for Growth

AYTU's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

AYTU's earnings are expected to grow with 35.64% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y57.75%

EPS Next 3Y35.64%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AYTU does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AYTU BIOPHARMA INC

NASDAQ:AYTU (2/21/2025, 8:02:32 PM)

1.35

-0.03 (-2.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)02-12 2025-02-12/amc

Earnings (Next)05-13 2025-05-13

Inst Owners30.53%

Inst Owner Change-99.87%

Ins Owners2.35%

Ins Owner Change0.13%

Market Cap8.30M

Analysts82.86

Price Target8.16 (504.44%)

Short Float %2.13%

Short Ratio4.36

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)117.92%

Min EPS beat(2)8.96%

Max EPS beat(2)226.87%

EPS beat(4)3

Avg EPS beat(4)44.38%

Min EPS beat(4)-78.65%

Max EPS beat(4)226.87%

EPS beat(8)5

Avg EPS beat(8)-428.35%

EPS beat(12)7

Avg EPS beat(12)-308.14%

EPS beat(16)8

Avg EPS beat(16)-261.19%

Revenue beat(2)2

Avg Revenue beat(2)10.13%

Min Revenue beat(2)2.24%

Max Revenue beat(2)18.02%

Revenue beat(4)3

Avg Revenue beat(4)4.57%

Min Revenue beat(4)-3.7%

Max Revenue beat(4)18.02%

Revenue beat(8)5

Avg Revenue beat(8)-1.48%

Revenue beat(12)7

Avg Revenue beat(12)-0.12%

Revenue beat(16)8

Avg Revenue beat(16)-1.05%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)20%

EPS NY rev (3m)213.04%

Revenue NQ rev (1m)-21.88%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-4.61%

Revenue NY rev (3m)-0.65%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.97
P/S	0.12
P/FCF	15.64
P/OCF	12.34
P/B	0.27
P/tB	N/A
EV/EBITDA	-0.11

EPS(TTM)-1.16

EYN/A

EPS(NY)1.4

Fwd EY103.51%

FCF(TTM)0.09

FCFY6.4%

OCF(TTM)0.11

OCFY8.11%

SpS11.18

BVpS5

TBVpS-3.12

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.51%
ROE	-17.04%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	67.43%
FCFM	0.77%

ROA(3y)-35%

ROA(5y)-27.17%

ROE(3y)-112.19%

ROE(5y)-78.65%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y14.82%

GM growth 5Y-0.72%

F-Score5

Asset Turnover0.59

Health

		Industry Rank	Sector Rank
Debt/Equity	0.45
Debt/FCF	29.85
Debt/EBITDA	5.94
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	28.57%
Profit Quality	N/A
Current Ratio	0.98
Quick Ratio	0.81
Altman-Z	-3.31

F-Score5

WACC18.78%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)71.29%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-550%

EPS Next Y125.68%

EPS Next 2Y57.75%

EPS Next 3Y35.64%

EPS Next 5YN/A

Revenue 1Y (TTM)-30.18%

Revenue growth 3Y7.28%

Revenue growth 5Y61.82%

Sales Q2Q%-29.27%

Revenue Next Year-17.49%

Revenue Next 2Y-5.54%

Revenue Next 3Y-3.13%

Revenue Next 5Y9.72%

EBIT growth 1Y3.24%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year631.37%

EBIT Next 3Y114.74%

EBIT Next 5YN/A

FCF growth 1Y101.91%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y102.42%

OCF growth 3YN/A

OCF growth 5YN/A

AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens